Almost three years after whiffing in a confirmatory study, Merck touts new data for Keytruda in HCC

Nicole DeFeudis

Editor

Keytruda’s accelerated approval in a common form of liver cancer looked shaky after the drug failed on two survival measures in a confirmatory study almost …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Almost three years after whiffing in a confirmatory study, Merck touts new data for Keytruda in HCC

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Sage sues Biogen days after $469M buyout offer

Ozempic makes list for next round of Medicare drug price negotiations

FDA approves AstraZeneca and Daiichi Sankyo’s ADC for breast cancer despite lack of survival benefit

What Trump's CMS can and can't change with the second round of drug price negotiations

Kathy High leads GV, ARCH-backed eye disease biotech; Arvinas commercial exec steps down

Roche's cardiometabolic chief warns against weight loss 'obsession' with GLP-1s

Al­most three years af­ter whiff­ing in a con­fir­ma­to­ry study, Mer­ck touts new da­ta for Keytru­da in HCC

Editor

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Almost three years after whiffing in a confirmatory study, Merck touts new data for Keytruda in HCC